Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

Phase 2TerminatedNCT05116046

Pfizer35 enrolled

Overview

All participants who completed the prior study to assess long-term safety, tolerability, pharmacokinetics and efficacy, and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll in this open-label extension (OLE) study for up to an additional 24 months of treatment. Approximately 63 participants will be offered to continue at the previously received dose of Recifercept either Low Dose Medium Dose High Dose or at the therapeutic dose once it is identified. Participants will attend the clinic monthly for 24 months. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements \& patient/caregiver quality of life questionnaires.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Achondroplasia

Interventions

Eligibility

Sex: ALLMin age: 15 MonthsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female participants between the ages of \>15 months to \<12 years inclusive, at Visit 1 (Screen 1). * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests lifestyle considerations and other study procedures. * Completed the C4181005 Phase 2 study. * Able to stand independently for height measurements (if ≥2 years of age at enrollment). Exclusion Criteria: * Presence of co-morbid conditions or circumstances that, in the opinion of the investigator, would affect interpretation of growth data or ability to complete the trial procedures. * Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Presence of severe obesity (body mass index (BMI) \>95th percentile on Hoover-Fong BMI charts) \[Hoover-Fong et al, 2008\]. * Known closure of long bone growth plates (cessation of height growth). * Body weight \>45 kg. * History of hypersensitivity to study intervention or any excipients. * History of any prior treatment with human growth hormone or related products (including insulin-like growth factor 1 \[IGF-1\]). * History of receipt of any treatment that are known to potentially affect growth (including oral steroids \>5 days in the last 6 months, high dose inhaled corticosteroids (\>800 mcg/day beclometasone equivalent) and medication for attention deficit hyperactivity disorder). * History of limb lengthening surgery (defined as distraction osteogenesis/Ilizarov/callostasis technique following submetaphyseal osteotomy to extend bone length). * Any limb lengthening/corrective orthopaedic surgery planned at any point during the trial period. * Less than 6 months since fracture or surgical procedure of any bone determined from the screening visit date. * Presence of any internal guided growth plates/devices. * History of removal of internal guided growth plates/devices within less than 6 months. * History of receipt of any other (except recifercept) investigational product for achondroplasia or that may affect growth/interpretation of growth parameters. * History of receipt of an investigational drug (not for achondroplasia/growth affecting) within the last 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

Locations (14)

Ocean Sleep Medicine

Irvine, California, United States

Long Beach Memorial Medical Center

Long Beach, California, United States

MemorialCare Sleep Disorders Center at Long Beach Memorial Medical Center

Long Beach, California, United States

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, United States

Nemours Children's Hospital, Delaware

Wilmington, Delaware, United States

Texas Childrens Hospital/Baylor College of Medicine

Houston, Texas, United States

Murdoch Children's Research Institute

Parkville, Victoria, Australia

UZ Leuven - Center of Human Genetics

Leuven, Flanders, Belgium

Antwerp University Hospital

Edegem, Belgium

Bispebjerg Hospital

Copenhagen, Denmark

...and 4 more locations

Outcomes

Primary Outcomes

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Severe AEs

An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. TEAE was an AE that occurred after initiation of study treatment that was not present at the time of treatment start or an AE that increased in severity after the initiation of medication, if the event was present at the time of treatment start emerges. SAE was an AE resulting in any of the following outcomes or considered medically significant: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or birth defect. Severe AEs were AEs that were medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated disabling, limiting self-care activities of daily living.

Time frame: From first dose of study drug up to 28 days after last dose of study drug (maximum up to 11 months)

Change From Baseline in Height at Month 24

Height was measured using anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual.

Time frame: Baseline, Month 24

Secondary Outcomes

Clearance (CL/F) of Recifercept

Clearance of a drug was a measure of the rate at which a drug is metabolised or eliminated by normal biological processes.

Time frame: Predose on Day 91, 181, 271, 361 and 451.

Change From Baseline in Sitting Height to Standing Height Ratio at Months 3, 6, 9

Sitting height to standing height ratio was calculated based upon the anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual.

Time frame: Baseline and Months 3, 6, 9

Change From Baseline in Arm Span to Height/Length Difference at Months 3, 6, 9

Height and length difference was calculated with anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual.

Time frame: Baseline and Months 3, 6, 9

Change From Baseline in Knee Height to Lower Segment Ratio at Months 3, 6, 9

Knee height was defined as the distance from the sole of the foot to the most anterior surface of the femoral condyles of the thigh (medial being more anterior), with the ankle and knee each flexed to a 90-degree angle. Lower segment of the leg included tibia and foot height

Time frame: Baseline and Months 3, 6, 9

Change From Baseline in Occipito-Frontal Circumference at Months 3, 6, 9

Occipito-frontal circumference was measured by anthropometric measurements. It was measured over the most prominent part on the back of the head (occiput) and just above the eyebrows (supraorbital ridges).

Time frame: Baseline and Months 3, 6, 9

Change From Baseline in Occipito-Frontal Distance to Occipito-mid-Face Measurements Ratio at Months 3, 6, 9

Occipito-frontal circumference was measured by anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual.